Amgen And Boston Children's Hospital Enter A Collaboration To Find New Genes And Drug Targets For Severe Pain Syndromes

CAMBRIDGE, Mass., Oct. 16, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Boston Children's Hospital today announced that they have entered into a neuroscience research collaboration aimed at identifying novel pain targets based on human genetic analyses. The one-year collaboration will focus on patients with genetic anomalies of pain sensitivity. Amgen will leverage its industry-leading expertise in genetic target identification and validation and will have access to Boston Children's Hospital's Division of Pain Medicine to identify patients with abnormal pain conditions. Amgen and Boston Children's Hospital will collaborate to validate the genetic findings as potential pain targets. "Tra...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news